PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
机构信息
Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
出版信息
JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.
Abstract
This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.
摘要
本队列研究评估了 PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。
相似文献
1
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.
2
There and back again: An immunotherapy tale.
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
3
KEYNOTE-024: Unlocking a pathway to lung cancer cure?
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
4
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Thorac Cancer. 2020 Jan;11(1):15-18. doi: 10.1111/1759-7714.13241. Epub 2019 Nov 7.
5
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3.
6
Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Clin Lung Cancer. 2018 Jan;19(1):12-16. doi: 10.1016/j.cllc.2017.06.015. Epub 2017 Jul 6.
7
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.
8
Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
Immunotherapy. 2018 Apr;10(5):345-347. doi: 10.2217/imt-2017-0180.
9
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Lung Cancer. 2019 Apr;130:10-17. doi: 10.1016/j.lungcan.2019.01.017. Epub 2019 Jan 31.
10
Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
J Cancer Res Clin Oncol. 2020 Jan;146(1):137-152. doi: 10.1007/s00432-019-03094-9. Epub 2019 Dec 7.
引用本文的文献
1
Risk factors for pneumonitis after the combination treatment of immune checkpoint inhibitors and thoracic radiotherapy.
BMC Pulm Med. 2025 Aug 25;25(1):404. doi: 10.1186/s12890-025-03871-y.
2
Construction of a checkpoint inhibitor-related pneumonia diagnostic model based on exhaled nitric oxide: a prospective observational study.
Transl Lung Cancer Res. 2025 May 30;14(5):1740-1755. doi: 10.21037/tlcr-2024-1085. Epub 2025 May 20.
3
The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.
J Clin Med. 2024 Dec 19;13(24):7777. doi: 10.3390/jcm13247777.
4
Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study.
Chin Med J (Engl). 2025 Sep 5;138(17):2130-2138. doi: 10.1097/CM9.0000000000003283. Epub 2024 Sep 23.
5
Immune checkpoint inhibitors with or without radiotherapy in metastatic non‑small cell lung cancer: A meta‑analysis and literature review.
Oncol Lett. 2024 Aug 9;28(4):489. doi: 10.3892/ol.2024.14622. eCollection 2024 Oct.
6
A Review of Immunotherapy in Non-Small-Cell Lung Cancer.
Curr Oncol. 2024 Jun 17;31(6):3495-3512. doi: 10.3390/curroncol31060258.
7
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy.
Oncoimmunology. 2021 Oct 21;10(1):1989790. doi: 10.1080/2162402X.2021.1989790. eCollection 2021.
8
Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8.
9
Radiotherapy and Immunotherapy in Lung Cancer.
Biomedicines. 2023 Jun 6;11(6):1642. doi: 10.3390/biomedicines11061642.
10
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
Cell Commun Signal. 2023 May 23;21(1):119. doi: 10.1186/s12964-023-01139-8.
本文引用的文献
1
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
2
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
3
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
4
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
5
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
6
Immunologic correlates of the abscopal effect in a patient with melanoma.
N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.
Zotero 插件